CASE PRESENTATION {#s1}
=================

A 19-mo-old twin Hispanic male was admitted to the hospital with fever (38.5°C) and compensated septic shock. Physical examination revealed approximately one dozen deep, indurated purpuric plaques with necrotic changes on the extremities and buttocks ([Fig. 1](#MCS003244SANF1){ref-type="fig"}). The patient\'s twin brother had died of septic shock, purpura fulminans, and disseminated intravascular coagulation in an outside hospital 1 d prior, after a 2-d hospitalization for similar symptoms. The twin brothers were born at 36-wk gestation and had not previously been hospitalized, but the mother reported that for the past 8 mo they had been frequently ill with respiratory tract infections requiring multiple courses of antibiotics. At the time of admission, the patient\'s weight was 12 kg, which fell into the 70th percentile for age-matched male controls. There was no family history of immunodeficiency.

![Skin lesions in the affected patient showing (*A*) left hand, (*B*) left thigh, and (*C*) right lower leg pseudomonal ecthyma gangrenosum.](MCS003244San_F1){#MCS003244SANF1}

Laboratory evaluation was significant for a white blood cell count of 2800 L^−1^ (reference 6000-14000) with 50% monocytes (2%--12%), 32% lymphocytes (30%--60%), 10% atypical lymphocytes (0%--10%), 2% segmented neutrophils (45%--70%), and 7% band neutrophils (0%--10%), C-reactive protein (CRP) level of 30.10 mg/dl (0.00--0.99), an erythrocyte sedimentation rate of 5 mm/h (0--10), procalcitonin level of 49.04 ng/ml (\<2.0), prothrombin time (PT) of 34.7 sec (11.4--14), and an international normalized ratio (INR) of 3.4 (0.9--1.2). Immunoglobulin levels were IgG \< 135 mg/dl (413--1112), IgA = 32 mg/dl (21--117), and IgM = 19 mg/dl (30--146).

The patient was started on vancomycin, ceftriaxone, doxycycline, and gentamicin, as the identity of the causative organism for this presumed community-acquired, life-threatening infection was not initially known. Cultures from the patient\'s blood were sterile. Filgrastim (G-CSF) was also administered subcutaneously at a dose of 5 mcg/kg daily for an absolute neutrophil count of 252 µl in the setting of overwhelming infection. Within the first 24 h of admission, the patient required intubation for respiratory failure as well as vasopressor therapy with multiple medications for fluid-refractory hypotension and poor perfusion. Because of concerns about hypercoagulability, intravenous immunoglobulin (IVIG) was initially held, but as the patient\'s condition worsened, a dose of 0.4 mg/kg of IVIG was given, which increased the patient\'s IgG level to 646 mg/dl.

A tissue culture obtained from a 5-mm punch biopsy of a cutaneous lesion grew *Pseudomonas aeruginosa* on the third hospital day. At that point, meropenem was added to the regimen and other antibiotics were eventually stopped. The diagnosis of pseudomonal ecthyma gangrenosum in this patient and the presumptive identical diagnosis in his deceased twin brother were highly suspicious for a primary immune deficiency, but the combination of neutropenia and low IgG and IgM levels did not conclusively point to one diagnosis. A lymphocyte enumeration panel was sent and resulted a CD19 absolute count of \<20 cells/µl (830--1880) the following day, consistent with absent B cells. Given the patient\'s critically ill state and the recent death of his twin, rapid trio whole-genome sequencing (rWGS) was undertaken simultaneously on the patient and his parents. In just more than 72 h, on the fourth hospital day, an apparently de novo hemizygous pathogenic variant (c.726dupT; p.Ile243TyrfsTer15; [Table 1](#MCS003178REGTB1){ref-type="table"}) in the *BTK* gene was detected and the patient was diagnosed with X-linked agammaglobulinemia (XLA, OMIM\#300300). As a result, filgrastim injections were discontinued and IVIG was administered to maintain IgG levels of \>800 mg/dl. On the same day (hospital day 4), verbal communication from the hospital where the patient\'s brother expired confirmed a positive blood culture for pseudomonas in the deceased twin. The patient\'s clinical status and level of cardiorespiratory support slowly improved on anti-pseudomonal antibiotics and IVIG therapy. He required regular debridement of the gangrenous lesions by plastic surgery and eventually underwent skin grafting. He was discharged from the hospital after a total of 5 mo.

###### 

Genomic findings

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene    Genomic location                              HGVS cDNA                HGVS protein         Zygosity     Parent of origin   Variant interpretation
  ------- --------------------------------------------- ------------------------ -------------------- ------------ ------------------ ------------------------
  *BTK*   NC_000023.10: Chr X:100615605 (GRCh37/hg19)   NM_000061.2: c.726dupT   NP_000052.1\         Hemizygous   De novo            Pathogenic
                                                                                 p.Ile243TyrfsTer15                                   

  ------------------------------------------------------------------------------------------------------------------------------------------------------------

TECHNICAL ANALYSIS AND METHODS {#s2}
==============================

The patient was enrolled in an IRB-approved research study. Blood was drawn immediately following consent for trio rWGS. The WGS testing was performed in a CAP/CLIA environment. DNA was subsequently extracted and sequenced on a HiSeq 4000 (Illumina). Rapid alignment and nucleotide variant calling was performed using the Dragen (Edico Genome) hardware and software ([@MCS003244SANC8]). Proband and parental samples were sequenced to a mean coverage of 40×. Variants were annotated and analyzed in Opal Clinical (Fabric Genomics) ([@MCS003244SANC2]). Initially, variants were filtered to retain those with allele frequencies of \<1% in the Exome Variant Server, 1000 Genomes Samples, and Exome Aggregation Consortium database (<http://evs.gs.washington.edu/EVS/2016>; [@MCS003244SANC6]). A gene panel was built in Phenolyzer ([@MCS003244SANC16]) using Human Phenotype Ontology (HPO) ([@MCS003244SANC7]). This panel included 1098 genes related to the following HPO terms: immunodeficiency (HP:0002721), neutropenia (HP:0001875), and sepsis (HP:0100806). Variants were further filtered to retain those mapping to these 1098 genes yielding 1068 proband calls (465 homozygous variants, 509 heterozygous inherited variants, and 15 heterozygous de novo variants). Manual curation revealed one variant as pathogenic by ACMG guidelines ([@MCS003244SANC12]). Specifically, the criteria invoked to score this variant as pathogenic included PVS1 (null variant in a gene where loss of function is a known mechanism of disease), PS2 (de novo variant), and PM2 (variant is absent from controls). This variant was confirmed by Sanger sequencing. The diagnosis was made by rWGS in 4 d.

VARIANT INTERPRETATION {#s3}
======================

This patient was found to be hemizygous for an apparently de novo known pathogenic frameshift variant (c.726dupT; p.Ile243TyrfsTer15) in the Bruton tyrosine kinase (*BTK*) gene. Pathogenic variants in *BTK* have been implicated in XLA (OMIM\#300300).

The de novo p.Ile243TyrfsTer15 pathogenic variant has been previously reported in a single individual with XLA ([@MCS003244SANC4]). p.Ile243TyrfsTer15 is absent from the ExAC and gnomAD population databases. The deletion causes a frameshift starting with codon Isoleucine 243, changes this amino acid to a tyrosine residue, and creates a premature stop codon at position 15 of the new reading frame. This pathogenic variant is predicted to cause loss of normal protein function through protein truncation or nonsense-mediated decay of the mRNA transcript.

METAGENOMICS {#s4}
============

Per institutional protocol, samples were processed via a standard clinically validated workflow, in addition to passing a battery of quality control (QC) scripts ([@MCS003244SANC3]). Using the reference human genome hg37dh, the QC metric of percent aligned reads passed at 98.8% and did not have a statistically significant deviation from median of past samples (*N* = 100). Given the pseudomonas sepsis phenotype, a metagenomics exploration was performed: After isolating the unaligned portion of reads, the most frequent, randomly sampled 500 reads were checked against the NCBI NR database, and significant similarity to *P. aeruginosa* genome was noted, whereas similarity to other pathogenic or nonpathogenic genomes was not found. The random sampling was drawn from the 500 most abundant reads (including duplicates). Then, all unaligned reads were aligned to reference *P. aeruginosa* PAO1 genome and 770 paired reads (654 unique; duplication rate 14%) were aligned. The qualities of the PAO1-aligned reads were not significantly different from those that aligned to the reference human genome (mean Q in read 1 = 36.28 and in read 2 = 36.04, aligned to PAO1; mean Q in read 1 = 36.09 and in read 2 = 35.66, aligned to hg19). For negative controls, unaligned portions of the patient\'s parental genomic DNA as well as genomic DNA from five random, unrelated persons were aligned to the reference PAO1 genome and 0--3 paired reads aligned in each (establishing the level of random alignments). Furthermore, the pattern of spatial distribution of the 770 reads from the proband\'s DNA sample to PAO1 genome was nearly uniform over the full length of the PAO1 genome (6.2 Mb, 25 ± 10 reads in each 200 kb window, i.e., ∼1 read/8 kb), resulting in the conclusion of the bona fide low-titer presence of *P. aeruginosa* in the proband\'s DNA sample ([Fig. 2](#MCS003244SANF2){ref-type="fig"}).

![Uniformly random spatial distribution of 770 reads from the proband\'s DNA sample (in which the *y*-axis represents the number of reads) aligned to the PAO1 genome (in which the *x*-axis is position Mb of the PAO1 genome; total size = 6.2 Mb).](MCS003244San_F2){#MCS003244SANF2}

DISCUSSION {#s5}
==========

Inherited defects of the immune system have an incidence of nearly 1 in 2000 children ([@MCS003244SANC1]). More than 300 primary immunodeficiencies (PIDs) are currently known, with the list rapidly expanding ([@MCS003244SANC1]; [@MCS003244SANC11]). Between 2013 and 2015 alone, 34 new gene defects for PID were identified ([@MCS003244SANC11]). The severity of infection in affected patients encompasses a spectrum ranging from recurrent respiratory illnesses to life-threatening systemic disease. Current consensus guidelines advocate for a stepwise approach to identifying a suspected PID ([@MCS003244SANC1]). However, identifying specific immunodeficiencies in this manner can take weeks to months and delay in diagnosis is significantly associated with increased mortality in these patients ([@MCS003244SANC5]). More recently, whole-exome sequencing has started to be explored as a high-throughput approach to diagnosing patients with suspected PIDs, with a diagnostic rate of up to 40% ([@MCS003244SANC14]). rWGS is emerging as a technology capable of making a specific genetic diagnosis in time to effect changes in acute clinical management. In our patient, the diagnosis of XLA was highly likely after the lymphocyte enumeration panel demonstrated absent B cells, and the next traditional step in the absence of rWGS would be to sequence the suspected gene (in this case, *BTK*), which takes several weeks to result. rWGS was able to make the diagnosis of XLA within 74.5 h.

XLA is a primary humoral immunodeficiency typically characterized by severe hypogammaglobinemia and recurrent bacterial infections ([@MCS003244SANC13]). It is caused by mutations in *BTK*, which encodes Bruton tyrosine kinase (Btk) ([@MCS003244SANC13]). Btk is a signal transduction molecule essential to B-cell lineage development, and its loss impairs the progression of pre-B cells to mature lymphocytes ([@MCS003244SANC10]). The lack of mature B lymphocytes results in insufficient immunoglobulin levels, and affected patients are unable to mount an appropriate antibody response to infection. Affected persons have normal levels of IgG at birth because of transplacental passage of maternal immunoglobulin, but become susceptible to bacterial and enteroviral infections as these levels gradually wane during the first year of life ([@MCS003244SANC10]). The diagnosis of XLA is suspected when laboratory investigations demonstrate absent B cells and a reduction in all classes of immunoglobulins, and it is confirmed by identifying a pathogenic variant in *BTK* ([@MCS003244SANC10]; [@MCS003244SANC13]).

The bacterial infections responsible for causing severe disease in patients with XLA are most frequently the pyogenic organisms *Streptococcus pneumoniae* and *Hemophilus influenzae* ([@MCS003244SANC17]; [@MCS003244SANC15]). Although uncommon, in addition to our patient there have been case reports of patients presenting with *P. aeruginosa* septicemia and ecthyma gangrenosum that were subsequently diagnosed with XLA ([@MCS003244SANC9]; [@MCS003244SANC17]).

The diagnosis of XLA by rWGS explained the patient\'s susceptibility to pseudomonal sepsis, indicated the appropriate management to be regular IVIG infusions, and may have prevented additional life-threatening infections. Retrospectively, it also provided an explanation for the death of his twin brother. The patient will be closely followed by immunology for the duration of his lifetime. In addition to monthly IVIG infusions, the patient will have to avoid live vaccinations and his treating physicians should have a low threshold for initiating antibiotic therapy when he is ill.

The metagenomic analysis identification of 770 *P. aeruginosa* genome sequences confirmed the presence of the bacterial DNA in the patient\'s bloodstream (DNAemia) and the clinical diagnosis of severe sepsis. Blood cultures in our patient, while receiving broad spectrum antibiotics, never grew *Pseudomonas*, and the bacterium was identified by culture of a skin biopsy of one of the gangrenous lesions. Patients with bacterial sepsis infrequently have skin lesions available for biopsy---in the absence of that sample for this patient, nucleic acid analysis would potentially have been the only acute method for identifying the responsible bacterial agent. This raises the possibility that rWGS could potentially have utility in identification of disease-causing organisms, especially in cases of culture-negative sepsis, and warrants further exploration.

SUMMARY {#s6}
=======

We report on a case of XLA presenting as pseudomonal ecthyma gangrenosum and severe sepsis that was diagnosed expeditiously by rWGS. rWGS identified a de novo frameshift variant (c.726dupT; p.Ile243TyrfsTer15) in *BTK*, the Bruton tyrosine kinase gene on Chromosome X. Thus, the proband was determined to be hemizygous for the monogenic disorder XLA. Additionally, metagenomic analysis of rWGS sequences that did not align to the human genome were found to align to the *P. aeruginosa* PAO1 genome.

ADDITIONAL INFORMATION {#s7}
======================

Data Deposition and Access {#s7a}
--------------------------

The variant was submitted to ClinVar ([http://www.ncbi.b\\nih.nlm.gov/clinvar](http://www.ncbi.b\nih.nlm.gov/clinvar)) and can be found under accession number SCV000809043.
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